The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry
Abstract
Objective: The risk of severe infection is a crucial factor in the assessment of the short‐term risk:benefit ratio of biologic drugs in rheumatoid arthritis (RA). There is no increase in severe infections in RA patients treated with rituximab (RTX) in controlled trials, but this has not yet been assessed in daily practice. We undertook this study to investigate the occurrence of and risk factors for severe infections in off‐trial patients using data from the AutoImmunity and Rituximab (AIR) registry. Methods: The AIR registry was set up by the French Society of Rheumatology. The charts of patients with severe infections were reviewed. Results: Of the enrolled patients, 1,303 had at least 1 followup visit at 3 months or later, with a mean ± SD followup period of 1.2 ± 0.8 years (1,629 patient‐years). Eighty‐two severe infections occurred in 78 patients (5.0 severe infections per 100 patient‐years), half of them in the 3 months following the last RTX infusion. Multivariate analysis showed that chronic lung disease and/or cardiac insufficiency (odds ratio 3.0 [95% confidence interval 1.3–7.3], P = 0.01), extraarticular involvement (odds ratio 2.9 [95% confidence interval 1.3–6.7], P = 0.009), and low IgG level (<6 gm/liter) before initiation of RTX treatment (odds ratio 4.9 [95% confidence interval 1.6–15.2], P = 0.005) were significantly associated with increased risk of a severe infection. Conclusion: The rate of severe infections in current practice is similar to that reported in clinical trials. The risk factors for severe infections include chronic lung and/or cardiac disease, extraarticular involvement, and low IgG before RTX treatment. This suggests that serum IgG should be checked and the risk:benefit ratio of RTX discussed for patients found to have low levels of IgG.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevoo, M. L. L., Van'T Hof, M. A., Kuper, H. H., Van Leeuwen, M. A., Van De Putte, L. B. A., & Van Riel, P. L. C. M. (1995) · Arthritis & Rheumatism · doi:10.1002/art.1780380107 · Cited by 6,243
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Self-citationEmery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Carson, K. R., Evens, A. M., Richey, E. A., Habermann, T. M., Focosi, D., Seymour, J. F., Laubach, J., Bawn, S. D., Gordon, L. I., Winter, J. N., et al. (2009) · Blood · doi:10.1182/blood-2008-10-186999 · Cited by 866
Dixon, W. G., Watson, K., Lunt, M., Hyrich, K. L., Silman, A. J., & Symmons, D. P. M. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21978 · Cited by 751
Infections in patients with rheumatoid arthritis treated with biologic agents
Listing, J., Strangfeld, A., Kary, S., Rau, R., von Hinueber, U., Stoyanova‐Scholz, M., Gromnica‐Ihle, E., Antoni, C., Herzer, P., Kekow, J., et al. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21386 · Cited by 681
Predictors of infection in rheumatoid arthritis
Doran, M. F., Crowson, C. S., Pond, G. R., O'Fallon, W. M., & Gabriel, S. E. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10529 · Cited by 560
Carson, K. R., Focosi, D., Major, E. O., Petrini, M., Richey, E. A., West, D. P., & Bennett, C. L. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70161-5 · Cited by 447
Curtis, J. R., Patkar, N., Xie, A., Martin, C., Allison, J. J., Saag, M., Shatin, D., & Saag, K. G. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22504 · Cited by 398
Keystone, E., Fleischmann, R., Emery, P., Furst, D. E., van Vollenhoven, R., Bathon, J., Dougados, M., Baldassare, A., Ferraccioli, G., Chubick, A., et al. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23059 · Cited by 337
Self-citationAskling, J., Fored, C. M., Brandt, L., Baecklund, E., Bertilsson, L., Feltelius, N., Cöster, L., Geborek, P., Jacobsson, L. T., Lindblad, S., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.062760 · Cited by 334
Dixon, W. G., Symmons, D. P. M., Lunt, M., Watson, K. D., Hyrich, K. L., & Silman, A. J. (2007) · Arthritis & Rheumatism · doi:10.1002/art.22808 · Cited by 307
Carmona, L., Descalzo, M. Á., Perez-Pampin, E., Ruiz-Montesinos, D., Erra, A., Cobo, T., & Gómez-Reino, J. J. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.067660 · Cited by 231
Lacaille, D., Guh, D. P., Abrahamowicz, M., Anis, A. H., & Esdaile, J. M. (2008) · Arthritis Care & Research · doi:10.1002/art.23913 · Cited by 187
Serum Immunoglobulins and Risk of Infection: How Low Can You Go?
Fürst, D. E. (2008) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.05.002 · Cited by 145
Curtis, J. R., Xi, J., Patkar, N. M., Xie, A., Saag, K. G., & Martin, C. K. (2007) · Arthritis & Rheumatism · doi:10.1002/art.23050 · Cited by 93
Dieguez‐Gonzalez, R., Akar, S., Calaza, M., Pérez-Pampín, E. M., Costas, J., Torres, M. L., Vicario, J. L., Velloso, M. L., Navarro, F., Narváez, J., et al. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.087304 · Cited by 43
Cited by
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Self-citationRamiro, S., Gaujoux-Viala, C., Nam, J. L., Smolen, J. S., Buch, M., Gossec, L., van der Heijde, D., Winthrop, K., & Landewé, R. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204575 · Cited by 701
The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment
Listing, J., Gerhold, K., & Zink, A. (2013) · Rheumatology · doi:10.1093/rheumatology/kes305 · Cited by 541
Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis
Buch, M. H., Smolen, J. S., Betteridge, N., Breedveld, F. C., Burmester, G., Dörner, T., Ferraccioli, G., Gottenberg, J.-E., Isaacs, J., Kvien, T. K., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.144998 · Cited by 453
Self-citationActive-comparator design and new-user design in observational studies
Yoshida, K., Solomon, D. H., & Kim, S. C. (2015) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2015.30 · Cited by 406
Metadata
- Authors
- Gottenberg, J. ‐., Ravaud, P., Bardin, T., Cacoub, P., Cantagrel, A., Combe, B., Dougados, M., Flipo, R. M., Godeau, B., Guillevin, L., Loët, X. L., Hachulla, E., Schaeverbeke, T., Sibilia, J., Baron, G., & Mariette, X.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2010-08-31
- Volume
- 62
- Issue
- 9
- Pages
- 2625-2632
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W1967360492
- Cited by
- 305
- References
- 19
- FWCI
- 15.66
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.